Display options
Cite
Dessai SB, Chakraborty S, Babu TV, et al. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian J Cancer. 2016;5(2):63-6doi: 10.4103/2278-330X.181629.
Dessai, S. B., Chakraborty, S., Babu, T. V., Nayanar, S., Bhattacharjee, A., Jones, J., Balasubramanian, S., & Patil, V. M. (2016). Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian journal of cancer, 5(2), 63-6. https://doi.org/10.4103/2278-330X.181629
Dessai, S B, et al. "Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin." South Asian journal of cancer vol. 5,2 (2016): 63-6. doi: https://doi.org/10.4103/2278-330X.181629
Dessai SB, Chakraborty S, Babu TV, Nayanar S, Bhattacharjee A, Jones J, Balasubramanian S, Patil VM. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian J Cancer. 2016 Apr-Jun;5(2):63-6. doi: 10.4103/2278-330X.181629. PMID: 27275450; PMCID: PMC4873699.
Copy Download .nbib Format: NLM
Share it on

South Asian J Cancer. 2016 Apr-Jun;5(2):63-6. doi: 10.4103/2278-330X.181629.

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.

South Asian journal of cancer

S B Dessai, S Chakraborty, T V S Babu, S Nayanar, A Bhattacharjee, J Jones, S Balasubramanian, Vijay M Patil

Affiliations

  1. Department of Surgical Oncology, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
  2. Department of Radiation Oncology, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
  3. Department of Cancer Imaging, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
  4. Department of Oncopathology and Translational Medicine, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
  5. Division of Clinical Research and Biostatistics, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
  6. Clinical Hematology and Medical Oncology, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.

PMID: 27275450 PMCID: PMC4873699 DOI: 10.4103/2278-330X.181629

Abstract

OBJECTIVE: There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to examine the toxicity and response rates of weekly paclitaxel and carboplatin as NACT in such cohort of patients.

METHODS: Study population included advanced ovarian cancer patients who were unlikely to tolerate 3 weekly paclitaxel and carboplatin and hence received weekly paclitaxel (80 mg/m(2)) and carboplatin AUC-2 as NACT. The data regarding the baseline characteristics, chemotherapy tolerance, completion rates, toxicity (Common Terminology Criteria for Adverse Events version 4.02), and radiological response rates are presented. SPSS version 16 was used for analysis. Descriptive statistics is presented.

RESULTS: Eleven patients received this schedule. Nine patients completed nine cycles of NACT. Except one, all patients completed NACT with an average relative dose intensity of >0.8. There was no chemotherapy-related mortality. Grade 3-4 life-threatening complications were seen in two patients. The post NACT response rate was 100%.

CONCLUSIONS: Weekly paclitaxel and carboplatin chemotherapy is safe and efficacious in patients who are unsuitable for 3 weekly paclitaxel and carboplatin chemotherapy schedules.

Keywords: Intolerable; metronomic; neoadjuvant chemotherapy; poor nutritional status; poor performance status

References

  1. Gynecol Oncol. 2005 Sep;98(3):403-8 - PubMed
  2. Am Soc Clin Oncol Educ Book. 2013;:227-35 - PubMed
  3. Gynecol Oncol. 2009 Feb;112(2):394-9 - PubMed
  4. J Ovarian Res. 2013 Jun 28;6(1):42 - PubMed
  5. Arch Gynecol Obstet. 2005 Dec;273(3):192-4 - PubMed
  6. Eur J Cancer. 2013 Dec;49(18):3831-8 - PubMed
  7. Gynecol Oncol. 2007 Jul;106(1):128-31 - PubMed
  8. Lancet Oncol. 2014 Apr;15(4):396-405 - PubMed
  9. Oncology. 2013;85(3):168-72 - PubMed
  10. N Engl J Med. 2010 Sep 2;363(10):943-53 - PubMed
  11. Br J Cancer. 2008 Apr 8;98(7):1197-203 - PubMed
  12. Crit Rev Oncol Hematol. 2008 Jun;66(3):229-36 - PubMed
  13. Gynecol Oncol. 2009 Aug;114(2):215-8 - PubMed
  14. Gynecol Oncol. 2011 Sep;122(3):532-5 - PubMed
  15. Lancet Oncol. 2013 Sep;14(10):1020-6 - PubMed
  16. Gynecol Oncol. 2013 May;129(2):310-7 - PubMed
  17. Gynecol Oncol. 2013 Apr;129(1):74-80 - PubMed

Publication Types